6ar0
From Proteopedia
(Difference between revisions)
m (Protected "6ar0" [edit=sysop:move=sysop]) |
|||
Line 1: | Line 1: | ||
- | '''Unreleased structure''' | ||
- | + | ==Structure of human SLMAP FHA domain== | |
+ | <StructureSection load='6ar0' size='340' side='right' caption='[[6ar0]], [[Resolution|resolution]] 1.08Å' scene=''> | ||
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[6ar0]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6AR0 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6AR0 FirstGlance]. <br> | ||
+ | </td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[6ar2|6ar2]]</td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6ar0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ar0 OCA], [http://pdbe.org/6ar0 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6ar0 RCSB], [http://www.ebi.ac.uk/pdbsum/6ar0 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6ar0 ProSAT]</span></td></tr> | ||
+ | </table> | ||
+ | == Disease == | ||
+ | [[http://www.uniprot.org/uniprot/SLMAP_HUMAN SLMAP_HUMAN]] Brugada syndrome. | ||
+ | == Function == | ||
+ | [[http://www.uniprot.org/uniprot/SLMAP_HUMAN SLMAP_HUMAN]] May play a role during myoblast fusion. | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | The Hippo pathway controls tissue growth and homeostasis through a central MST-LATS kinase cascade. The scaffold protein SAV1 promotes the activation of this kinase cascade, but the molecular mechanisms remain unknown. Here, we discover SAV1-mediated inhibition of the PP2A complex STRIPAKSLMAP as a key mechanism of MST1/2 activation. SLMAP binding to autophosphorylated MST2 linker recruits STRIPAK and promotes PP2A-mediated dephosphorylation of MST2 at the activation loop. Our structural and biochemical studies reveal that SAV1 and MST2 heterodimerize through their SARAH domains. Two SAV1-MST2 heterodimers further dimerize through SAV1 WW domains to form a heterotetramer, in which MST2 undergoes trans-autophosphorylation. SAV1 directly binds to STRIPAK and inhibits its phosphatase activity, protecting MST2 activation-loop phosphorylation. Genetic ablation of SLMAP in human cells leads to spontaneous activation of the Hippo pathway and alleviates the need for SAV1 in Hippo signaling. Thus, SAV1 promotes Hippo activation through counteracting the STRIPAKSLMAP PP2A phosphatase complex. | ||
- | + | SAV1 promotes Hippo kinase activation through antagonizing the PP2A phosphatase STRIPAK.,Bae SJ, Ni L, Osinski A, Tomchick DR, Brautigam CA, Luo X Elife. 2017 Oct 24;6. pii: e30278. doi: 10.7554/eLife.30278. PMID:29063833<ref>PMID:29063833</ref> | |
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | [[Category: | + | </div> |
+ | <div class="pdbe-citations 6ar0" style="background-color:#fffaf0;"></div> | ||
+ | == References == | ||
+ | <references/> | ||
+ | __TOC__ | ||
+ | </StructureSection> | ||
+ | [[Category: Luo, X]] | ||
+ | [[Category: Ni, L]] | ||
+ | [[Category: Fha]] | ||
+ | [[Category: Hippo]] | ||
+ | [[Category: Signaling protein]] | ||
+ | [[Category: Slmap]] |
Revision as of 07:10, 4 July 2018
Structure of human SLMAP FHA domain
|
Categories: Luo, X | Ni, L | Fha | Hippo | Signaling protein | Slmap